Generic Name: talazoparib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.

General Info

Pfizer Talzenna talazoparibTalzenna interferes with poly (ADP-ribose) polymerase, or PARP proteins, which play a role in DNA repair. Inhibiting PARP leads to more DNA breaks in cancer cells, which can halt cell division.

The EMBRACA trial showed that Talzenna slows disease progression and improves response rates compared with chemotherapy in people with advanced or metastatic breast cancer. The median duration of progression-free survival was 8.6 months in the Talzenna group versus 5.6 months in the chemotherapy group—a 46 percent lower likelihood of disease progression.


Dosing Info:

Talzenna is taken as a once-daily capsule with or without food.

Side Effects

Common side effects include fatigue, headache, nausea, vomiting, diarrhea, decreased appetite, hair loss and blood cell deficiencies. Talzenna can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. The Talzenna label includes a warning about myelodysplastic syndrome or acute myeloid leukemia, which occurred in a very small number of people who took the drug in clinical studies.

For More Info:

Patient Assistance Program Info:

Last Reviewed: October 16, 2018